Teva Threatened by Generic Compaxone

Sandoz, a generic drug manufacturer affiliated with Novartis, has teamed up with Momenta to attempt to bring a generic version of Copaxone to market.

Copaxone is a patented drug based on Israeli applied academic research that was developed by Teva, and is used to treat multiple schlerosis. Teva is the world’s most successful generic drug manufacturer, and, by manufacturing generic medicines has hurt Novartis’ sales in the past. This time round, Novartis is hurting Teva, with Teva’s shares having dropped some 10% since Thursday.

Teva is not giving up without a battle however. Teva maintains that their patents are valid until 2014 in the US and 2015 in Europe and are threatening to sue. Some analysts believe that the patent will be difficult to defend in court. That as may be, the drug is very complex to manufacture, and it is not clear that Momenta and Sandoz will manage to synthesize an effective version. 

Copaxone sold in excess of $500 million last quarter and accounts for maybe 20% of Teva’s earnings.



Categories: Intellectual Property, Israel, Israel IP, Israel Related, News, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: